NCT00252746View on ClinicalTrials.gov

ZD6474 Phase IIa Dose Finding Multicentre Study

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Non Small Cell Lung Carcinoma
Interventions
DRUG

ZD6474 (vandetanib) 100mg

once daily oral dose

DRUG

ZD6474 (vandetanib) 200mg

once daily oral dose

DRUG

ZD6474 (vandetanib) 300mg

once daily oral dose

Trial Locations (7)

Unknown

Research Site, Matsuyama

Research Site, Isehara

Research Site, Okayama

Research Site, Sayama

Research Site, Toyonaka

Research Site, Sunto-gun

Research Site, Tokyo

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00252746 - ZD6474 Phase IIa Dose Finding Multicentre Study | Biotech Hunter | Biotech Hunter